53 patents
Page 3 of 3
Utility
Multimeric bispecific binding molecules specific for CD20 and CD3
28 Sep 20
This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.
Bruce Alan Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang
Filed: 3 Mar 16
Utility
Binding Molecules with Modified J-chain
12 Aug 20
The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.
Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
Filed: 15 Jan 20
Utility
IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
29 Jul 20
This disclosure provides an IgM antibody or IgM-like antibody comprising a variant J-chain and/or variant IgM heavy chain constant regions that can confer increased serum half-life upon the antibody.
Ramesh BALIGA, Bruce KEYT, Dean NG
Filed: 22 Mar 20
Utility
Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
22 Jun 20
This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
Beatrice Tien-Yi Wang, Max A. Schwarzer, Bruce Alan Keyt, Ramesh Baliga
Filed: 19 Jan 16
Utility
Modified J-chain
17 Jun 20
The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.
Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
Filed: 26 Feb 20
Utility
Binding molecules with modified J-chain
13 Apr 20
The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an AD-ME-modulating moiety, and their uses.
Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
Filed: 29 Sep 16
Utility
Multi-valent hepatitis B virus antigen binding molecules and uses thereof
30 Mar 20
This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain.
Stephen F. Carroll, Ramesh Baliga, Dean Ng, Bruce Keyt
Filed: 24 Mar 16
Utility
Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
24 Feb 20
This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain.
Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
Filed: 14 Apr 16
Utility
Multimeric CD40 Binding Molecules and Uses Thereof
6 Nov 19
This disclosure provides dimeric, pentameric, and hexameric CD40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
Ramesh BALIGA, Beatrice Tien-Yi Wang, Dalya Rivka ROSNER, Bruce Alan Keyt
Filed: 18 Jul 17
Utility
Multimeric CD137/4-1BB Binding Molecules and Uses Thereof
6 Nov 19
This disclosure provides dimeric, pentameric, and hexameric CD137/4-1BB agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
Bruce Alan Keyt, Ramesh BALIGA, Beatrice Tien-Yi Wang
Filed: 18 Jul 17
Utility
ANTI-PD-L1 Antibodies
6 Nov 19
Aspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling.
Bruce KEYT, Leonard George PRESTA, Ramesh BALIGA
Filed: 8 May 17
Utility
Multimeric Gitr Binding Molecules and Uses Thereof
30 Oct 19
This disclosure provides dimeric, pentameric, and hexameric GITR agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
Beatrice Tien-Yi WANG, Bruce Alan Keyt, Ramesh BALIGA
Filed: 19 Jul 17
Utility
Multimeric OX40 Binding Molecules and Uses Thereof
30 Oct 19
This disclosure provides dimeric, pentameric, and hexameric OX40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
Beatrice Tien-Yi WANG, Dalya Rivka Rosner, Ramesh BALIGA, Bruce Alan Keyt
Filed: 19 Jul 17